SOMERSET, N.J., Oct. 25, 2010 (GLOBE NEWSWIRE) -- inVentiv Commercial, a division of inVentiv Health and the industry leader in outsourced sales teams to the pharmaceutical industry, announced today that it has been selected by international specialty pharmaceuticals company BTG International Inc to provide a sales team, as well as training and fulfillment services, for the company's CroFab® and DigiFab® products. CroFab® is an antidote used to treat envenomation from Crotalid snakes, and DigiFab® is a treatment for life-threatening digoxin (digitalis) toxicity or overdose.
"inVentiv is extremely pleased to be collaborating with BTG," said Eric Sirota, President of inVentiv Commercial. "We look forward to putting our experienced sales teams and expert training and fulfillment services to work for CroFab® and DigiFab®, vitally important products for toxicity and venom treatment."
"We look forward to working with inVentiv Commercial," said Dan Schneider, Vice President of Sales & Marketing, BTG. "Their experience in recruiting and deploying high-quality sales teams will be an asset to BTG as we focus on promoting these important products."
About inVentiv Health
inVentiv Health, Inc. is a leading, global provider of data-driven, outsourced solutions to the pharmaceutical, life sciences and healthcare industries. inVentiv's full suite of marketing, sales, clinical development and post-approval solutions drive speed and effectiveness across all phases of the product lifecycle, leading to quicker development and superior results throughout product launch and commercialization. inVentiv's client roster consists of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payer companies. For more information, visit .
The inVentiv Health, Inc. logo is available at
CONTACT: inVentiv Health, Inc. Investors/Corporate: Joe Massaro, CFO (732) 537-4804 investor@inventivhealth.com Media: Marcia Frederick (614) 543-6281 mfrederick@inventivhealth.com